Cyclacel's 15-minute chart triggers RSI overbought and Bollinger Bands narrowing.

Cyclacel's 15-minute chart has triggered an overbought reading on the Relative Strength Index (RSI) and narrowing Bollinger Bands as of September 10, 2025, at 14:45. This suggests that the stock price has risen too rapidly and exceeds its fundamental support level, with a decreasing magnitude of price fluctuations.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), a micro-cap biotech company, has seen significant shareholder approvals and notable technical indicators recently. On September 10, 2025, at 14:45, the company's 15-minute chart triggered an overbought reading on the Relative Strength Index (RSI) and narrowing Bollinger Bands. This suggests that the stock price has risen too rapidly and may be overvalued, exceeding its fundamental support level with decreasing price fluctuations Cyclacel Pharmaceuticals shareholders approve share issuance and name change^[1].

At a special meeting held on September 9, 2025, shareholders approved several key proposals. The first proposal authorized the issuance of Cyclacel common stock to Fitters Parent, as outlined in the Exchange Agreement. The second proposal authorized the potential issuance of more than 20% of the company’s outstanding common stock to comply with Nasdaq Listing Rule 5635(a). Lastly, shareholders approved an amendment to change the corporate name to Bio Green Med Solution, Inc. .

Cyclacel Pharmaceuticals has also made other significant announcements. The company filed an 8-K report with the Securities and Exchange Commission, submitting audited consolidated financial statements for the quarter ending March 31, 2025. Additionally, the company appointed SFAI Malaysia PLT as its new auditor following the dismissal of Bush & Associates CPA LLP. The 2025 annual meeting of shareholders saw the re-election of five directors, each securing at least 99.97% of the votes cast. Shareholders also approved changes to the company’s equity plan .

The company's financial health, as indicated by a healthy current ratio of 5.77, shows resilience. However, its overall financial health score indicates weakness, suggesting a need for cautious investment consideration .

Investors should closely monitor Cyclacel Pharmaceuticals' technical indicators and financial health metrics to make informed decisions. The narrowing Bollinger Bands and overbought RSI reading suggest a potential price correction, while the shareholder approvals and recent announcements indicate the company's active management and strategic planning.